ID

32721

Beschrijving

Study ID: 101877 Clinical Study ID: SAS101877 Study Title: A randomised, open label, 5-way crossover study to assess the systemic exposure of FP and salmeterol from SERETIDE/ADVAIR 250 without spacer, with Aerochamber -Plus and with -Max spacer, with VOLUMATIC spacer and SERETIDE/ADVAIR 500 DISKUS/ACCUHALER in adult subjects with mild or intermittent asthma Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: fluticasone propionate/salmeterol Trade Name: Advair DISKUS,Seretide Accuhaler; Viani,Seretide Diskus,Seretide Accuhaler,Seretide,Advair DISKUS Study Indication: Asthma The study consists of 5 treatment periods and a follow-up visit. The Screening includes Session 1 Treatment Period 1 includes Session 2 Treatment Period 2 includes Session 3 Treatment Period 3 includes Session 4 Treatment Period 4 includes Session 5 Treatment Period 5 includes Session 6 The Follow-up includes Session 7. This document contains the alcohol urin test, urin cotinine test and drug screen form. The Drug of Abuse has to be filled in for period 1, 2, 3, 4 and 5. The alcohol urin test and urin cotinine test have to be filled in at screening (session 1).

Trefwoorden

Versies (4)

1. 13/11/2018 13/11/2018 -
2. 16/11/2018 16/11/2018 -
3. 22/11/2018 22/11/2018 -
4. 22/11/2018 22/11/2018 -

Houder van rechten

GlaxoSmithKline

Geüploaded op

13 de novembro de 2018

DOI

Voor een aanvraag inloggen.

Licentie